Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
ValiRx PLC - life sciences company focused on early-stage cancer therapeutics and women’s health - Notes that its subsidiary Inaphaea BioLabs Limited wins a ‘revenue-bearing’ contract for the provision of patient derived cell based services with a US-based biotech company. ‘The contract is a multi-stage project and encompasses analysis and provision of RNA data, acquired as part of the scientific package from Imagen Therapeutics, in addition to bespoke cell-based screening in the laboratory,’ ValiRx explains.
Andrew Carnegie, head of Strategic Commercial Development at Inaphaea, says: ‘It’s encouraging to have secured this contract in the exciting area of immuno-oncology, which will be a great opportunity to showcase our skills and leveraging our patient derived cells in this area. The US biotech market is a strong location to seek clients for Inaphaea and this contract is a positive step towards establishing our brand in further geographical regions.’
Current stock price: 2.68 pence per share, up 3.0% on Monday afternoon in London
12-month change: down 65%
Copyright 2024 Alliance News Ltd. All Rights Reserved.